• Vaxcyte recently dosed the first participant in its Phase 1, first-in-human trial of VAX-A1, a prophylactic Group A Streptococcus vaccine candidate being tested in about 80 healthy adults in Australia to assess safety, tolerability and initial immune responses.
• This marks an early but important step in expanding Vaxcyte’s pipeline beyond pneumococcal vaccines into a second high-burden infectious disease area with no approved vaccine.
• We’ll now examine how initiating first-in-human testing for VAX-A1 may influence Vaxcyte’s investment narrative and longer-term pipeline balance.

Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.

Vaxcyte Investment Narrative Recap

To own Vaxcyte, you have to believe its pneumococcal franchise can translate late stage trial readouts into approvals while the balance sheet supports years of heavy R&D. The first-in-human VAX-A1 trial is an encouraging diversification step, but it does not change the near term focus on OPUS-1 data and cash burn as the key catalyst and risk, respectively, so its immediate impact on the story is modest.

Among recent developments, the completion of enrollment across the OPUS-1, OPUS-2 and OPUS-3 Phase 3 trials in March 2026 feels most relevant here. It reinforces that VAX-31 remains the primary value driver while VAX-A1 is still very early, setting up a period where investors will be watching both late stage PCV outcomes and initial Group A Strep data to judge how balanced the longer term pipeline might become.

Yet investors should also consider how rising R&D and manufacturing costs could strain Vaxcyte’s cash runway and financing needs...

Vaxcyte’s narrative projects $224.6 million revenue and $28.1 million earnings by 2029. This requires an earnings increase of about $794.7 million from -$766.6 million today.

Uncover how Vaxcyte's forecasts yield a $109.00 fair value, a 130% upside to its current price.

Exploring Other Perspectives

The most bearish analysts were assuming only US$15.3 million of revenue and US$1.7 million of earnings by 2029, so compared with the consensus narrative they paint a far more cautious picture of Vaxcyte’s prospects, especially if early VAX A1 uncertainty and extended trial timelines delay any meaningful contribution from this new program.

Explore 3 other fair value estimates on Vaxcyte - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Vaxcyte research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Vaxcyte research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vaxcyte's overall financial health at a glance.

No Opportunity In Vaxcyte?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.